We confirmed that CELSR3 was significantly upregulated in PCa (primary PCa and metastatic castration-resistant prostate cancer) when compared to benign prostatic hyperplasia in the PCTA dataset (Figure 1A; P<0.001). Here, CELSR3 is linked to benign prostatic hyperplasia.